
Safety and Antiviral Activity of Albinterferon Alfa-2b Dosed Every Four Weeks in Genotype 2/3 Chronic Hepatitis C Patients
Keywords: اینترفرون ها; AE; adverse event; alb-IFN; albinterferon alfa-2b; ANC; absolute neutrophil count; BMI; body mass index; CHC; chronic hepatitis C; ETR; end-of-treatment response; Hb; hemoglobin; HOMA-IR; homeostasis model assessment of insulin resistance; IFN; interferon